[1]Storrow AB,Gilbler WB.Chest pain centers: diagnosis of acute coronary syndromes[J].Ann Emerg Med,2000,35(5):449-461.
[2]Baldus S,Heeschen C,Meinertz T,et al.Myeloperoxidase serum levels predict risk in patient with acute coronary syndromes[J].Circulation,2003,108(12):1440-1445.
[3]Braunwald E,Antman E M,Beasley J W,et al.ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina)[J].J Am Coll Cardiol,2002,40(7):1366-1374.
[4]中华医学会检验分会 卫生部全国临床检验标准委员会临床应用准则专家委员会等.冠状动脉疾病和心力衰竭时心脏标志物临床检测应用建议[J].中华检验医学杂志,2006,29(9):774-777.
[5]Venge P,Lagerqvist B,Diderholm E,et al.Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease(a FRISCⅡ substudy)[J].Am J Cardiol,2002,89(9):1035-1041.
[6]Jernberg T,Stridsberg M,Venge P,et al.N-terminal pro brain natriuretic peptide on admission for early risk stratifica-tion of patients with chest pain and no ST-segment elevation[J].J Am Coll Cardiol,2002,40(3):437-445.
[7]Morrow DA,de Lemos JA,Blazing M A,et al.Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease[J].JAMA,2005,294(22):2866-2871.
[8]Lindahl B,Toss H,Siegbahn A,et al.Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease[J].N Engl J Med,2000,343(16):1139-1147.
[9]Sabatine M S,Morrow D A,De Lemos J A,et al.Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin Ⅰ,C-reactive protein,and B-type natriuretic peptide[J].Circulation,2002,105(15):1760-1763.